Data supporting the application demonstrated that the investigational subcutaneous formulation improved quality of life, reduced administration time, lowered rates of
Dr. Reddy’s launches OTC, store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets in the U.S. Market
Dr.Reddy’s has launched OTC store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration.
Algiax Pharmaceuticals appoints Prof. Claudia Sommer and Dr. Klaus-Dieter Langner to join its Scientific Advisory Board
Clinical neuropathic pain expert Prof. Sommer and long-time pain pharma industry expert Dr. Langner to consult Algiax Pharmaceuticals in the
Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters
Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new €400 million fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion.
Sensient Technologies today announced the election of Carol Jackson to its Board of Directors, effective December 1, 2019.
Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.1
Key data now being collected to support endpoint assessment for future gene therapy clinical trial NEW YORK–(BUSINESS WIRE)–Neurogene Inc., a
Quotient Sciences and global investment firm Permira today announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum.
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity – two common nerve agents
Nexien BioPharma was granted patent for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.
Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors
Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license agreement for Inflection’s first-in-class PIM/PI3K/mTOR inhibitors.